Name: KPV 10mg
Brand: RetaLABS
SKU: kpv-10mg
Price: 55.00 AUD
Availability: InStock
Rating: 5.0 (4 reviews)

Question 1

What is KPV used for in research?

Accepted Answer

KPV (Lys-Pro-Val) is primarily researched for its anti-inflammatory properties as a C-terminal fragment of the immunomodulatory neuropeptide α-MSH (alpha-melanocyte-stimulating hormone). As a stable tripeptide, KPV retains the core immunomodulatory activity of α-MSH while offering improved resistance to enzymatic degradation — making it a practical research tool for sustained anti-inflammatory intervention in cell culture and animal models. Studies have investigated its role in attenuating intestinal inflammation in DSS-induced colitis and TNBS-induced colitis models, where KPV administration has been associated with reduced mucosal damage, decreased pro-inflammatory cytokine expression (including TNF-α and IL-6), and preservation of epithelial barrier integrity. Its small molecular weight (~356 Da) allows potential penetration of mucosal surfaces and cellular membranes in ways not available to larger peptide anti-inflammatories. KPV is also studied for wound healing — both systemic and topical administration models have examined its ability to reduce inflammatory phase duration and accelerate epithelialisation in cutaneous injury models.

Question 2

How does KPV exert its anti-inflammatory effects?

Accepted Answer

Research suggests KPV exerts anti-inflammatory effects through multiple converging molecular mechanisms. At the transcriptional level, it inhibits activation of NF-κB — the central transcription factor governing expression of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. Inhibition of NF-κB nuclear translocation reduces the transcriptional output of these inflammatory mediators, attenuating the acute inflammatory response in cell culture models. As a fragment of α-MSH, KPV may also operate through melanocortin receptor pathways (particularly MC1R and MC3R, expressed on monocytes, macrophages, and T-cells) to promote anti-inflammatory signalling via cAMP-mediated pathways that downregulate macrophage activation. In intestinal research models, KPV has been shown to reduce neutrophil infiltration into inflamed mucosa, suggesting effects on chemokine-mediated immune cell recruitment in addition to direct cytokine suppression. The combined NF-κB inhibitory and melanocortin receptor-mediated mechanisms provide complementary research angles for studying KPV's immunomodulatory profile.

Question 3

How should KPV be stored?

Accepted Answer

Lyophilised KPV should be stored at −20°C, protected from moisture and light, to maintain long-term stability. As a small tripeptide with molecular weight of approximately 356 Da, KPV exhibits good intrinsic stability in the lyophilised state — the absence of large hydrophobic domains or disulfide bridges reduces susceptibility to the aggregation pathways that affect larger peptides at elevated temperatures. Nonetheless, for maximum shelf life, frozen storage is recommended. Vials should be sealed until use. Once the septum is punctured and bacteriostatic water has been added, refrigerate the reconstituted solution at 2–8°C and use within four weeks. The tripeptide's compact structure confers reasonable aqueous stability at refrigerator temperatures over this period. For research programmes requiring very long-term KPV availability, the lyophilised stock vial should remain frozen at −20°C while small working aliquots are reconstituted periodically, rather than reconstituting the entire vial and storing the solution for extended periods.

Question 4

Is KPV suitable for gut inflammation research models?

Accepted Answer

KPV is particularly well-characterised for intestinal inflammation research and is among the most studied α-MSH-derived fragments in gut biology models. Its small molecular weight (~356 Da) and tripeptide stability allow systemic delivery and potential mucosal penetration, making it practical for both intraperitoneal and oral administration routes in rodent models. Published preclinical studies have examined KPV's effects in DSS (dextran sodium sulfate)-induced colitis, TNBS (trinitrobenzene sulfonic acid)-induced colitis, and spontaneous colitis models — collectively demonstrating reductions in disease activity index scores, histological inflammation scores, and pro-inflammatory cytokine levels in colonic tissue. Mechanistic studies in these models have attributed KPV's effects to NF-κB pathway inhibition, reduced neutrophil infiltration, and preservation of tight junction protein expression (including claudin and occludin), which supports epithelial barrier integrity. These well-defined research endpoints make KPV a valuable positive control compound for researchers investigating novel anti-inflammatory agents in IBD models.

KPV 10mg

Customer Reviews

Product Specifications

Frequently Asked Questions

Research Guides